Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health, NuPathe, AcelRx Pharmaceuticals, and Momenta Pharmaceuticals

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Solta Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc. (NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Solta Medical, Inc. Research Report

On December 16, 2013, Solta Medical, Inc. (Solta Medical) announced that it has entered into a definitive agreement with Valeant Pharmaceuticals International, Inc. (Valeant), pursuant to which Valeant will acquire all of the Company's outstanding common stock for $2.92 per share in cash or total consideration of approximately $250 million. Solta Medical reported that the acquisition is expected to close in Q1 2014 and to be immediately accretive to Valeant's cash EPS, once completed. Commenting on the acquisition agreement, Mark Sieczkarek, Chairman of the Board and Interim CEO of Solta Medical said, "Our Board of Directors has determined that this all cash offer is in the best interest of our stockholders. We further believe the acquisition by Valeant provides the best opportunity for Solta Medical brands and our employees to achieve their full potential while generating a significant, near term return for our stockholders." The Full Research Report on Solta Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c5ec_SLTM

--

Opko Health, Inc. Research Report

On December 16, 2013, Opko Health, Inc. (Opko Health) announced that it has entered into an agreement to acquire Laboratorio Arama de Uruguay Limitada (Arama). Opko Health reported that the acquisition is expected to add to its South American presence in the Mercosur economic region while further complementing its business activities in Chile, Mexico, and Brazil. Phillip Frost, M.D., Chairman and CEO of Opko Health, said, "We continue to broaden our commercial prospects through investments that complement our existing businesses and bolster the global reach of our robust product pipeline." Frost continued, "This acquisition will allow Opko to establish a footprint in Uruguay and facilitate future sales and commercial expansion into neighboring Argentina. In the near term, Arama provides another platform for the commercialization of our 4Kscore, a novel panel of biomarkers and associated algorithm to more accurately detect and grade possible prostate cancers." Opko Health reported that the transaction is expected to close in January 2014. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/cd43_OPK

--

NuPathe, Inc. Research Report

On December 16, 2013, NuPathe, Inc. (NuPathe) announced that it has entered into a definitive agreement with Endo Health Solutions (Endo), under which Endo will acquire NuPathe for $2.85 per share in cash for a total consideration of approximately $105 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time. Armando Anido, NuPathe CEO, commented, "Our team has worked very hard to develop products that we believe will provide significant clinical advantages over current treatments for patient populations facing diseases of the central nervous system. We believe this acquisition by Endo will increase the potential for ZECUITY to make a meaningful difference for patients we have worked so hard to serve." NuPathe expects the transaction to be completed in early 2014. The Full Research Report on NuPathe, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/d5b0_PATH

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 16, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that it has entered into a commercial collaboration with Grunenthal GmbH, covering the territory of the European Union, certain other European countries and Australia for ZALVISO (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital, hospice, nursing home or other medically supervised setting. AcelRx reported that its lead program, ZALVISO, is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. The Company said that it will receive an upfront payment of $30 million, and is eligible to receive approximately $220 million in additional milestone payments, based upon successful regulatory and product development efforts and net sales target achievements. The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1454_ACRX

--

Momenta Pharmaceuticals Inc. Research Report

On December 12, 2013, Momenta Pharmaceuticals Inc. (Momenta) announced the appointment of Michael Franken, M.D. as President, Biosimilars Business. According to the Company, Dr. Franken will oversee the operational management of biosimilars program, including its collaboration with Baxter International Inc., strategic planning, P&L responsibility, and other supporting activities. Commenting on the appointment, Craig Wheeler, Momenta's President and CEO said, "Michael brings more than 17 years of broad experience to the company, including a valuable combination of operations skills, market expertise and business development. With this focus, we will better align our resources and expertise to create an even stronger collaboration with Baxter to advance this core business." The Full Research Report on Momenta Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c334_MNTA

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED